Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Cabozantinib, Ipilimumab, Nivolumab; Drug · Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Duarte, California • Orange, California • Cleveland, Ohio + 2 more

Conditions: Phase IB, Avutometinib, RAS Pathway, Endometrial
Interventions: Avutometinib, defactinib, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peritoneal Malignant Mesothelioma
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Pemetrexed Disodium, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Chicago, Illinois • Danville, Illinois + 31 more

Conditions: Methylmalonic Acidemia (MMA)
Interventions: Not listed
Lead sponsor: Genespire Srl; Industry
Eligibility: Up to 16 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Stroke, Stroke, Acute
Interventions: MCI, Sham MCI; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Pain
Interventions: Educational Session; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Mosunetuzumab, ClonoSEQ; Drug · Device
Lead sponsor: Danielle Wallace; Other
Eligibility: 70 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pancreatic Adenocarcinoma, Weight Loss
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alcohol Use Disorder
Interventions: Intravenous Alcohol; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Suicidal Ideation
Interventions: Brief Cognitive Behavioral Therapy (BCBT), Treatment as usual (TAU); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Peripheral Artery Disease (PAD)
Interventions: REGN7508, REGN9933, Placebo, Rivaroxaban; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 7,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 30
States / cities: Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 26 more

Conditions: Congenital Heart Disease, Congenital Vascular Disorder, Congenital Cardiomyopathy, Pregnancy Related
Interventions: Masimo Smart Wristband; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obese Patients, Tobacco Use, Veterans, Family History of Esophageal Cancer, Barrett Esophagus
Interventions: Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy.; Diagnostic Test
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Systemic Lupus Erythematosus (Sle)
Interventions: Nicotinamide Riboside; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Sclerosing Cholangitis
Interventions: Hymecromone; Drug
Lead sponsor: Aparna Goel; Other
Eligibility: 14 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Stanford, California

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Internet-Based Intervention, Questionnaire Administration, Virtual Technology Intervention; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions: Observation; Other
Lead sponsor: Insel Gruppe AG, University Hospital Bern; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Sickle Cell Disease, Adverse Childhood Experiences, Breastfeeding
Interventions: Breastfeeding support group, Observation; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neoplasm
Interventions: Contribution to Caregivers Well-Being, Control; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pre-Eclampsia, Pregnancy Loss
Interventions: Aspirin 162 mg, Aspirin 81mg; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: Registry; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 8 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions: Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Search by objective public record fields.

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT Gene

Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

MIVetsCan: Can-Coach Trial (Phase 2)

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Motivation for IV Alcohol Self-Administration in Humans

Development of a Treatment Prognosis Calculator for the Prevention of Suicide

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables

Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

A Virtual Community Health Educator for Increasing Clinical Trial Referrals Among Cancer Patients and Their Caregivers

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

Early Life Exposures Among Children With Sickle Cell Disease

CARE Study: Cancer, Asian Americans, and Relationship Enrichment

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)